Evidence map›Paper›PMID 42823492›Full record

Observational studyEuropean journal of clinical pharmacology2026

Personalizing mycophenolate therapy: genetic determinants and practical limited sampling strategy for pediatric lupus nephritis.

Lu Zhang, Lizhi Chen, Chen Ye, Xiaohong Liu, Zhijun Huang, Kejing Tang, Pan Chen, Xiaoyun Jiang

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lu Zhang *Department of Pharmacy, Zhuhai Center for Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.
Lizhi Chen *Department of Pediatric Nephrology and Rheumatology, the First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China.
Chen Ye *Department of Pharmacy, the First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China.
Xiaohong LiuDepartment of Pediatric Nephrology and Rheumatology, the First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China.
Zhijun HuangDepartment of Pediatric Nephrology and Rheumatology, the First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China.
Kejing TangDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China.
Pan ChenDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China. Chenp73@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-9324-5490
Xiaoyun JiangDepartment of Pediatric Nephrology and Rheumatology, the First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, People's Republic of China. jxiaoy@mail.sysu.edu.cn.

Funding

China Higher Education Institution Industry-University-Research Innovation Fund 2025XH101Chronic Disease Management Research Project of National Health Commission Capacity Building and Continuing Education Center GWJJMB202510025012Research Project Established by Chinese Pharmaceutical Association Hospital Phamacy Department CPA-Z05-ZC-2025002Research project on high quality development of Hospital pharmacy, National Institute of Hospital Administration, NHC, China NIHAYS2505Zhuhai Medical Research Project 2520009000044
6 · The paper itself

Abstract

objectiveTo identify determinants of mycophenolic acid (MPA) pharmacokinetics (PK) in pediatric patients with lupus nephritis (LN), and to develop a limited sampling strategy (LSS) for estimating MPA-AUC

methodsA single-center observational study enrolled biopsy-proven LN receiving mycophenolate mofetil (MMF) at least 7 consecutive days. Univariate analysis were performed to assess associations between MPA PK parameters and demographics, genetic polymorphisms, clinical variables. LSS models for predicting MPA-AUC

resultsStatistically significant correlations were observed between MPA-AUC

conclusionReduced MPA exposure was associated with MMF doses < 20 mg·kg⁻

Indexed as

Immunosuppressive AgentsLupus NephritisMycophenolic AcidAdolescentArea Under CurveChildChild, PreschoolFemaleHepatocyte Nuclear Factor 1-alphaHumansMaleModels, BiologicalPolymorphism, Single NucleotidePrecision MedicineHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanImmunosuppressive AgentsMycophenolic AcidGenetic polymorphismLupus nephritisMycophenolic acidPediatricsPharmacokinetics

Identifiers

PMID42823492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.